M4di variant
By optimizing the M4Di receptor through molecular biology and protein engineering, enhancing ligand sensitivity and prolonging desensitization time, the persistence problem of the M4Di receptor in chemogenetic therapy was solved, improving therapeutic efficacy and safety.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- GENANS BIOTECHNOLOGY CO LTD
- Filing Date
- 2025-12-25
- Publication Date
- 2026-07-02
AI Technical Summary
Existing M4Di receptors are limited in their application to chemogenetic therapy due to limitations in ligand sensitivity, response intensity, and desensitization time, resulting in inconsistent therapeutic effects. High doses of CNO may induce nonspecific effects, affecting the practicality and efficacy of long-term treatment.
By optimizing the M4Di receptor through molecular biology and protein engineering, we can enhance its sensitivity to ligands and prolong the desensitization time. By combining it with excitatory neuron-specific promoters, we can improve targeting and inhibitory efficacy and reduce the risk of side effects.
This enables sustained therapeutic effects with lower doses of ligands, reduces nonspecific effects, and enhances the long-term application potential of chemogenetic therapy, particularly in pain management.
Smart Images
Figure 00000066_0000 
Figure 00000066_0001 
Figure 00000067_0000